Organogenesis Holdings (ORGO) Cash from Investing Activities (2018 - 2026)

Organogenesis Holdings' Cash from Investing Activities history runs 9 years deep, the most recent figure standing at -$3.1 million for Q1 2026.

• On a quarterly basis, Cash from Investing Activities rose 13.24% year-over-year to -$3.1 million in Q1 2026; TTM through Mar 2026 was -$13.7 million, a 19.54% decrease from a year earlier, with the FY2025 full-year figure at -$14.2 million, down 41.06% from the prior year.
• Cash from Investing Activities advanced to -$3.1 million in Q1 2026 per ORGO's latest filing, from -$4.7 million in the prior quarter.
• Across five years, Cash from Investing Activities topped out at -$1.9 million in Q2 2024 and bottomed at -$10.7 million in Q4 2022.
• The 5-year median for Cash from Investing Activities is -$3.6 million (2025), against an average of -$5.0 million.
• Across the five-year window, Cash from Investing Activities sank 103.86% in 2022 and surged 74.93% in 2024, its largest moves.
• Year by year, Cash from Investing Activities stood at -$10.7 million in 2022, then surged by 68.81% to -$3.3 million in 2023, then dropped by 1.11% to -$3.4 million in 2024, then plunged by 38.41% to -$4.7 million in 2025, then surged by 32.37% to -$3.1 million in 2026.
• Per Business Quant, the three latest ORGO Cash from Investing Activities figures stand at -$3.1 million (Q1 2026), -$4.7 million (Q4 2025), and -$2.2 million (Q3 2025).